SAB Biotherapeutics (SABS) Competitors

$3.68 -0.01 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.63 -0.05 (-1.44%)

As of 07:26 PM Eastern

SABS vs. IRWD, RIGL, XOMA, VSTM, and MYGN

Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Ironwood Pharmaceuticals (IRWD), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

: Ironwood Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ironwood Pharmaceuticals $296.15M 2.57 $24.02M $0.13 35.92
SAB Biotherapeutics $1.32M 142.04 $13.27M -$2.32 N/A
: Ironwood Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
: In the previous week, SAB Biotherapeutics had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 5 mentions for Ironwood Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 0.78 beat Ironwood Pharmaceuticals' score of -0.07 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
SAB Biotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Ironwood Pharmaceuticals presently has a consensus target price of $6.23, indicating a potential upside of 33.48%. SAB Biotherapeutics has a consensus target price of $10.50, indicating a potential upside of 185.33%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Ironwood Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.43
SAB Biotherapeutics
2 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.63
: Ironwood Pharmaceuticals has a net margin of 8.11% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of 15.17% beat Ironwood Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals 8.11% -13.72% 10.95%
SAB Biotherapeutics N/A 15.17% 12.51%
: 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.57	$24.02M	$0.13	35.92
SAB Biotherapeutics	$1.32M	142.04	$13.27M	-$2.32	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
SAB Biotherapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	8.11%	-13.72%	10.95%
SAB Biotherapeutics	N/A	15.17%	12.51%

Summary

SAB Biotherapeutics beats Ironwood Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

: Rigel Pharmaceuticals has a net margin of 124.72% compared to SAB Biotherapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 79.84% beat SAB Biotherapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals 124.72% 79.84% 42.74%
SAB Biotherapeutics N/A 15.17% 12.51%
: Rigel Pharmaceuticals presently has a consensus price target of $45.67, indicating a potential upside of 62.57%. SAB Biotherapeutics has a consensus price target of $10.50, indicating a potential upside of 185.33%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Rigel Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
SAB Biotherapeutics
2 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.63
: Rigel Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
: In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 6 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.78 beat Rigel Pharmaceuticals' score of 0.77 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
SAB Biotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Rigel Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rigel Pharmaceuticals $294.28M 1.76 $367.02M $18.91 1.49
SAB Biotherapeutics $1.32M 142.04 $13.27M -$2.32 N/A
: 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	124.72%	79.84%	42.74%
SAB Biotherapeutics	N/A	15.17%	12.51%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SAB Biotherapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.76	$367.02M	$18.91	1.49
SAB Biotherapeutics	$1.32M	142.04	$13.27M	-$2.32	N/A

Summary

Rigel Pharmaceuticals beats SAB Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to XOMA Royalty?

SAB Biotherapeutics (NASDAQ:SABS) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

: XOMA Royalty has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAB Biotherapeutics $1.32M 142.04 $13.27M -$2.32 N/A
XOMA Royalty $52.15M 9.52 $31.71M $1.46 28.53
: 7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 8.9% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: XOMA Royalty has a net margin of 45.75% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of 15.17% beat XOMA Royalty's return on equity.
Company Net Margins Return on Equity Return on Assets
SAB Biotherapeutics N/A 15.17% 12.51%
XOMA Royalty 45.75% 10.32% 3.49%
: SAB Biotherapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
: SAB Biotherapeutics presently has a consensus target price of $10.50, indicating a potential upside of 185.33%. XOMA Royalty has a consensus target price of $53.75, indicating a potential upside of 29.02%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe SAB Biotherapeutics is more favorable than XOMA Royalty.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAB Biotherapeutics
2 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.63
XOMA Royalty
0 Sell rating(s)

5 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.29
: In the previous week, SAB Biotherapeutics had 4 more articles in the media than XOMA Royalty. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 2 mentions for XOMA Royalty. SAB Biotherapeutics' average media sentiment score of 0.78 beat XOMA Royalty's score of 0.42 indicating that SAB Biotherapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SAB Biotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
XOMA Royalty
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	142.04	$13.27M	-$2.32	N/A
XOMA Royalty	$52.15M	9.52	$31.71M	$1.46	28.53

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	15.17%	12.51%
XOMA Royalty	45.75%	10.32%	3.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA Royalty	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SAB Biotherapeutics beats XOMA Royalty on 10 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Verastem?

SAB Biotherapeutics (NASDAQ:SABS) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

: SAB Biotherapeutics has higher earnings, but lower revenue than Verastem. Verastem is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAB Biotherapeutics $1.32M 142.04 $13.27M -$2.32 N/A
Verastem $30.91M 16.94 -$209.47M -$3.20 N/A
: In the previous week, SAB Biotherapeutics had 4 more articles in the media than Verastem. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 2 mentions for Verastem. SAB Biotherapeutics' average media sentiment score of 0.78 beat Verastem's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SAB Biotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verastem
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 25.1% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 1.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: SAB Biotherapeutics presently has a consensus price target of $10.50, suggesting a potential upside of 185.33%. Verastem has a consensus price target of $16.60, suggesting a potential upside of 178.52%. Given SAB Biotherapeutics' higher possible upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Verastem.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAB Biotherapeutics
2 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.63
Verastem
1 Sell rating(s)

1 Hold rating(s)

5 Buy rating(s)

2 Strong Buy rating(s)
2.89
: SAB Biotherapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
: SAB Biotherapeutics' return on equity of 15.17% beat Verastem's return on equity.
Company Net Margins Return on Equity Return on Assets
SAB Biotherapeutics N/A 15.17% 12.51%
Verastem N/A -1,849.88% -111.53%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	142.04	$13.27M	-$2.32	N/A
Verastem	$30.91M	16.94	-$209.47M	-$3.20	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Verastem	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	15.17%	12.51%
Verastem	N/A	-1,849.88%	-111.53%

Summary

SAB Biotherapeutics beats Verastem on 10 of the 14 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Myriad Genetics?

SAB Biotherapeutics (NASDAQ:SABS) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

: 7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: SAB Biotherapeutics has higher earnings, but lower revenue than Myriad Genetics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAB Biotherapeutics $1.32M 142.04 $13.27M -$2.32 N/A
Myriad Genetics $824.50M 0.58 -$365.90M -$3.94 N/A
: SAB Biotherapeutics currently has a consensus price target of $10.50, suggesting a potential upside of 185.33%. Myriad Genetics has a consensus price target of $8.94, suggesting a potential upside of 77.68%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Myriad Genetics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAB Biotherapeutics
2 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.63
Myriad Genetics
1 Sell rating(s)

6 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.27
: SAB Biotherapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -44.38%. SAB Biotherapeutics' return on equity of 15.17% beat Myriad Genetics' return on equity.
Company Net Margins Return on Equity Return on Assets
SAB Biotherapeutics N/A 15.17% 12.51%
Myriad Genetics -44.38% -6.35% -3.73%
: In the previous week, Myriad Genetics had 4 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 10 mentions for Myriad Genetics and 6 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.78 beat Myriad Genetics' score of -0.05 indicating that SAB Biotherapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SAB Biotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Myriad Genetics
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
: SAB Biotherapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	142.04	$13.27M	-$2.32	N/A
Myriad Genetics	$824.50M	0.58	-$365.90M	-$3.94	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Myriad Genetics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	15.17%	12.51%
Myriad Genetics	-44.38%	-6.35%	-3.73%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

SAB Biotherapeutics beats Myriad Genetics on 12 of the 16 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$188.01M	$3.39B	$6.24B	$11.86B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	N/A	38.85	29.04	28.48
Price / Sales	142.04	157.28	477.10	60.43
Price / Cash	10.80	57.88	27.62	36.52
Price / Book	1.16	7.03	9.67	6.67
Net Income	$13.27M	$23.62M	$3.55B	$332.64M
7 Day Performance	4.25%	3.67%	1.70%	2.01%
1 Month Performance	-5.15%	7.17%	5.62%	9.19%
1 Year Performance	116.47%	67.04%	34.42%	39.59%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	2.8097 of 5 stars	$3.68 -0.3%	$10.50 +185.3%	N/A	$188.01M	$1.32M	N/A	140	Upcoming Earnings
IRWD Ironwood Pharmaceuticals	2.1629 of 5 stars	$4.20 +4.0%	$6.23 +48.4%	N/A	$658.76M	$296.15M	32.31	220	Upcoming Earnings
RIGL Rigel Pharmaceuticals	2.7708 of 5 stars	$30.56 +0.2%	$45.67 +49.4%	N/A	$563.83M	$294.28M	1.62	160	News Coverage Earnings Report
XOMA XOMA Royalty	3.6034 of 5 stars	$40.86 -2.6%	$68.25 +67.0%	N/A	$500.10M	$52.15M	27.99	10	Upcoming Earnings High Trading Volume
VSTM Verastem	2.0004 of 5 stars	$5.46 -1.4%	$16.60 +204.0%	N/A	$486.65M	$30.91M	N/A	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. IRWD, RIGL, XOMA, VSTM, and MYGN

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to XOMA Royalty?

Summary

How does SAB Biotherapeutics compare to Verastem?

Summary

How does SAB Biotherapeutics compare to Myriad Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. IRWD, RIGL, XOMA, VSTM, and MYGN

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to XOMA Royalty?

Summary

How does SAB Biotherapeutics compare to Verastem?

Summary

How does SAB Biotherapeutics compare to Myriad Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools